Spyre Therapeutics (SYRE) Other Operating Expenses (2023 - 2026)

Spyre Therapeutics' Other Operating Expenses history runs 3 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• Quarterly Other Operating Expenses changed N/A year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (changed N/A YoY) and the FY2025 annual result came in at $10.0 million, changed N/A from the prior year.
• Other Operating Expenses was $30.0 million for Q1 2026 at Spyre Therapeutics, up from $10.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $130.5 million in Q2 2023 and bottomed at $1.8 million in Q4 2023.
• A 3-year average of $37.4 million and a median of $14.6 million in 2023 frame the typical range for Other Operating Expenses.